Production (Stage)
Atara Biotherapeutics, Inc.
ATRA
$7.80
$0.3054.07%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 38.01M | -12.69M | -21.91M | -19.05M | -31.75M |
Total Depreciation and Amortization | 1.80M | 1.10M | 1.23M | 1.33M | 1.39M |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 14.17M | 9.53M | 10.13M | 10.46M | 12.48M |
Change in Net Operating Assets | -82.11M | -22.41M | 6.56M | -3.38M | -11.73M |
Cash from Operations | -28.14M | -24.47M | -3.99M | -10.65M | -29.61M |
Capital Expenditure | -- | -90.00K | 0.00 | -29.00K | -127.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 17.20M | 3.47M | -16.67M | 7.23M | 14.84M |
Cash from Investing | 17.20M | 3.38M | -16.67M | 7.20M | 14.72M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -250.00K | -235.00K | -197.00K | -233.00K | -227.00K |
Issuance of Common Stock | -- | -- | 50.81M | 93.00K | 9.37M |
Repurchase of Common Stock | -- | -93.00K | -- | -- | -6.00K |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | 0.00 | -14.82M | -184.00K | 15.00M |
Cash from Financing | -250.00K | -328.00K | 35.79M | -324.00K | 24.14M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -11.19M | -21.42M | 15.14M | -3.77M | 9.25M |